麻豆传媒

Bernard (Bernie) W. Chang, M.D., Director of Baltimore’s Plastic & Reconstructive Surgery at Mercy, also leads The Breast Reconstruction and Restoration Center at Mercy. Dr. Bernie Chang is Board Certified in Plastic Surgery and General Surgery. He pioneered and advanced surgical treatment options like DIEP flap surgery for breast reconstruction. With a skilled and highly specialized team of doctors, Mercy's Plastic Surgery and Breast Reconstruction Centers are known as one of the Mid-Atlantic’s best in breast reconstruction and restoration, cosmetic medicine and plastic surgery. As the Assistant Director of The Hoffberger Breast Center at Mercy in Baltimore, Dr. Bernie Chang works closely with the Breast Center doctors to provide seamless care for those women who choose immediate breast reconstruction after breast surgery. The industry-leading expertise of Dr. Chang and the renowned reputation of the physicians of The Breast Center result in choices that women may not find elsewhere. With more than 20 years of medical experience, Dr. Chang offers women peace of mind in breast reconstruction and restoration. His quiet thoughtfulness and attention to the needs of his patients provide a calming touch that helps each woman focus on her treatment options and recovery. His expertise is in helping women reclaim their feminine form and personal self-esteem after a diagnosis and treatment for breast cancer. Women say they have regained their physical and emotional balance in the care of Dr. Chang. Dr. Chang has performed DIEP flap breast reconstruction surgery for decades and his leadership is widely known. DIEP flap breast reconstruction surgery is one of the most widely performed breast shaping options for women. Dr. Chang is also skilled in other microsurgical flap procedures including: DIEP flap SGAP flap & Bilateral SGAP Flap IGAP flap TUG flap Latissimus flap Dr. Bernie Chang’s surgical expertise attracts surgical fellows from across the nation to train in the renowned Fellowship Program at Mercy in breast reconstruction and surgical flap treatment options.

Vadim Gushchin, M.D., serves as Director of The Melanoma and Skin Cancer Center at Mercy as well as Director of Gastrointestinal Oncology, a division of Surgical Oncology at Mercy Medical Center in Baltimore, Maryland. Dr. Gushchin offers expertise in complex malignancies and is a skilled cancer surgeon. He is exceptionally accomplished in minimally invasive surgery – most notably in da Vinci Robotic Surgery – as well as in traditional open surgery techniques. Gastrointestinal Cancer (GI Cancers), melanoma – more commonly known as skin cancer, and thyroid cancer are among the many cancer diagnoses Dr. Gushchin treats. To determine the best treatment option for his surgical oncology patients, Dr. Gushchin carefully evaluates each patient’s risk factors, medical history, current clinical condition, surgical alternatives and post-surgical recovery options in order to fully develop a thorough, personalized care plan. Dr. Gushchin comforts and compassionately walks his patients through the treatment steps needed to care for melanoma, thyroid and parathyroid disease, peritoneal surface malignancies (abdominal tumors), and recurring tumors within the colon, rectum and liver. Dr. Gushchin is well-recognized for his experience in treating complex cancers with HIPEC (Hyperthermic Intraperitoneal Chemotherapy). Dr. Gushchin trained under the internationally renowned surgical oncologist Dr. Paul Sugarbaker to master this procedure, which involves cytoreductive surgery followed by a heated chemotherapy solution to reduce and eliminate tumors. Dr. Gushchin has participated in over 150 HIPEC surgeries and provides patients expertise in complicated HIPEC surgeries including repeat HIPEC surgeries, simultaneous liver resections at the time of HIPEC as well as other advanced surgical treatments in conjunction with HIPEC treatment. An international presenter and teacher, Dr. Gushchin has educated physicians around the world on HIPEC treatment and has organized teaching courses for the treatment of peritoneal surface malignancies (complex abdominal cancers that can be treated with HIPEC). As an extension of his knowledge and compassion, Dr. Gushchin has been instrumental in setting up treatment centers for peritoneal surface malignancies in other parts of the world including Lithuania, Siberia and Ukraine. Dr. Vadim Gushchin is one of Mercy Medical Center’s top surgical oncologists. He utilizes many of the latest innovations in technology and research to provide state-of-the-art treatment options to his patients. Dr. Gushchin brings expertise in robotic surgery, using the da Vinci robot. Patients who qualify for da Vinci robot surgery typically experience the benefits of a more precise and exacting surgery, a less invasive procedure, shorter hospital stay and faster recovery. Dr. Vadim Gushchin leads a multidisciplinary team of experts at The Melanoma and Skin Cancer Center at Mercy to treat a wide range of skin cancers. As an experienced oncology surgeon and talented cancer specialist, he uses the Isolated Limb Infusion technique to try to save an arm or leg that has been aggressively attacked by skin cancer. Isolated Limb Infusion, also known as ILI, offers patients a remarkable alternative approach to metastatic melanoma on a limb. This type of skin cancer commonly leads to amputation or a disfiguring result. Dr. Gushchin and his patients know this doesn’t always have to be the case. Isolated Limb Infusion gives Dr. Gushchin a fighting chance to save his patients’ affected arms and/or legs, reduce or shrink the cancerous tumor and avoid the need for a more radical surgery.

Paul R. Lucas, M.D., is an experienced vascular surgeon and Director of The Vascular Center at Mercy in Baltimore, Maryland. He is Board Certified in Vascular Surgery and has been recognized as a Top Doc by Baltimore magazine numerous times. Dr. Lucas leads a team of vascular surgeons and technologists who specialize in the diagnosis and treatment of patients with diseased blood vessels. His patients admire his attentive and caring professionalism and he is noted for taking the time to be sure they understand their condition and treatment options. Dr. Paul Lucas utilizes the latest technologies to care for patients experiencing vascular disorders. He specializes in Venefit™ (formerly known as VNUS Closure™) and Veingogh© procedures for varicose vein removal and is continuously seeking advanced diagnostic and treatment options for more efficient care. Dr. Paul Lucas is a Registered Physician in Vascular Interpretation and was instrumental in the establishment of Mercy's nationally accredited Vascular Laboratory at The Vascular Center at Mercy. Patients can be screened at all of Mercy’s physician office locations throughout Greater Baltimore, making diagnosis and subsequent scheduling for treatment convenient. Using non-invasive Doppler ultrasound equipment, lab technologists screen patients for circulatory problems like mini-strokes, circulation issues, leg swelling or pain, blood clots and aneurysms.

Kevin M. Audlin, M.D., is a Board Certified, experienced doctor and skilled surgeon in The Gynecology Center at Mercy Medical Center in Baltimore, Maryland. He also serves as Director of The Endometriosis Center at Mercy, a division of The Gynecology Center, focused primarily on the diagnosis and treatment of endometrial and fibroid disorders. Dr. Audlin has presented his surgical techniques and endometriosis findings at many national and international conferences.

Throughout Dr. Kevin Audlin鈥檚 medical career he has cared for and managed the GYN health needs of women in the neighborhoods of Towson, Overlea and Reisterstown.

As a result of years of practice and thousands of annual patient exam visits, Drs. Audlin and Barrueto have believed there was a clear need for more focused attention on endometriosis and other pelvic reconstruction conditions. They established The Endometriosis Center at Mercy so that women would have access to state-of-the-art treatment options, including laparoscopic and robotic minimally invasive surgical techniques focusing on excision of endometriosis while preserving the uterus and fertility whenever possible. Mercy offers fully appointed surgery suites equipped with leading edge technology, as well as recovery and inpatient rooms for post-surgical recovery that are welcoming and provide a homelike atmosphere for women and their loved ones.

Dr. Audlin also is the first doctor in the mid-Atlantic region to use the groundbreaking low impact laparoscopic surgery to treat GYN conditions. This state-of-the-art minimally invasive technique utilizes micro surgical tools and 3 mm incisions, resulting in 40% or greater decrease in incision size than typical laparoscopic surgery.

Low impact laparoscopic surgery incisions are approximately the length of a sesame seed. Low impact laparoscopy also can reduce the effects of surgery since it requires less inflation of the abdomen during surgery and uses micro-fine tools. This groundbreaking technique in coordination with the use of 3D imagery and NBI technology most often provides Dr. Audlin the opportunity to offer the best cosmetic options as well as leading edge management of many common gynecologic problems. This type of surgery may be used for endometriosis, hysterectomy, myomectomy, ovarian cysts and oophorectomy (removal of one or both ovaries). Dr. Audlin will use your medical history, risk factor and a thorough examination to help determine whether low impact laparoscopy is a suitable treatment option for your condition.

How do you select the best doctor for your GYN care, especially if you have been diagnosed with endometriosis, fibroids, or other endoscopic and pelvic reconstruction conditions? Dr. Audlin encourages women to carefully select a doctor who is Board Certified, is specially trained in the care of routine and complex gynecologic diagnoses and a doctor who is extensively educated and experienced in minimally invasive surgical treatment options.

Named a "Top Doc" by Baltimore magazine, Dr. Kevin Audlin is proud his medical education and clinical achievements have given him first-hand knowledge to care for women鈥檚 GYN needs.  He also believes concern, a comforting bedside manner, compassion and treating women with dignity and respect are at the heart of Mercy care.

Dr. Audlin has in-depth training and experience in treating the many levels of gynecologic care 鈥� from routine annual exams to pelvic reconstruction using the da Vinci Robot. Minimally invasive procedures using laparoscopic and robotic surgery have become the gold standard of care to treat many GYN conditions. Dr. Audlin has exceptional skill and knowledge in treating Interstitial Cystitis, a painful bladder condition.

One treatment option that requires the expertise of a gynecologist like Dr. Audlin is called sacral nerve stimulation. This is where a thin wire is put in place and delivers an electrical impulse to the bladder to help it perform properly. This procedure is often compared to what a pacemaker does for the heart.

Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System Cancer Care. He joined Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise.

With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health.

Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium.

As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally.

Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits.

Dr. Angela Alistar is a board-certified medical oncologist with Atlantic Hematology Oncology, Atlantic Medical Group.  Dr. Alistar is Medical Director of GI Medical Oncology at Morristown Medical Center where she is also Medical Director of the Phase 1 Breakthrough Treatment Center.  Her research focus is related to immuno-oncology and cancer metabolism in gastrointestinal cancer such as: pancreatic tumors, cholangiocarcinoma, colorectal, esophageal, gastric cancer and hepatocellular carcinoma. Her clinical research projects involved active collaborative efforts with other medical departments, such as radiation oncology and surgical oncology, as well as genomics and cancer biology.

Recently, she has published in Lancet Oncology the results of a Phase 1 clinical study in pancreatic cancer that are very promising for advancing the field for this disease. This study has shown impressive synergy of a novel agent, CPI -613 in combination with chemotherapy. She is co-leading the national multi-site, randomized study of this promising combination, as well as many other phase 1-3 clinical trials.

Dr. Alistar comes to Atlantic Health System from Wake Forest School of Medicine where she had a heavy emphasis on clinical trials and clinical research. At Wake Forest, she led the GI oncology disease oriented team as a gastrointestinal medical oncology physician and researcher, bringing cutting-edge treatments to patients. She designed, secured funding for and conducted five investigator-initiated therapeutic clinical trials, with four of them being phase one. Her work involved maintenance of a sponsor-investigator investigational new drug. She is passionate about Precision Oncology and Immunotherapies and seeks to identify novel treatment strategies for her patients.

Past positions at Wake Forest include being a member of the Translational Cancer Genomics Committee, the GI Tumor Board, Internal Medicine Grand Rounds, and the Hepatobiliary Oncology Committee. She is a member of several health care organizations, such as the American Society of Clinical Oncology, the American Society of Hospice and Palliative Care Medicine, and the American Society of Hematology, among many others. As well, she is a member and advisor for several other health care institutions. She was recently awarded the "Danny Danielson Translational Innovation Award" by Hoosier Cancer Research Network for her commitment to clinical research. 

She received her medical degree from University of Medicine and Pharmacy, Cluj Napoca, Romania and her residency at Englewood Hospital and Medical Center, NJ, where she was chief resident. After her residency, she completed a hematology oncology fellowship at Mount Sinai School of Medicine, Tisch Cancer Institute. She is affiliated with Atlantic Medical Group, and is a participating provider of Atlantic Accountable Care Organization, and sees patients at Morristown Medical Center.

As CEO of Patients Beyond Borders, Josef Woodman has spent the past twelve years researching and vetting international options for quality, affordable medical care. He has met and consulted with ministries and key stakeholders in the world's leading medical travel destinations, touring more than 200 medical facilities in 35 countries. Co-founder of MyDailyHealth (1998) and Ventana Communications (1987), Woodman's pioneering background in publishing, healthcare and technology has allowed him to compile a wealth of information and knowledge about international medical care, telemedicine, wellness, integrative medicine and consumer-directed healthcare.

Woodman has lectured at the UCLA School of Public Health, Harvard Medical School, Duke Fuqua School of Business, Scientific American and the International Society for Travel Medicine. He has keynoted and moderated conferences on medical tourism and global healthcare in 20 countries. He has appeared in numerous print and broadcast media, including The Economist, The New York Times, CNN, ABC 麻豆传媒, Fox 麻豆传媒, Huffington Post, Barron's, The Wall Street Journal, and more.

Woodman is an outspoken advocate of affordable, high-quality medical and preventative care for healthcare consumers worldwide.

Ken Paulson is director of the Free Speech Center, former dean of the College of Media and Entertainment at Middle Tennessee State University (MTSU) and former editor-in-chief of USA Today, where he remains a columnist writing about First Amendment and media issues. He is the host of “The Songwriters,” a television show on PBS, featuring interviews with Nashville Songwriters Hall of Fame inductees. Paulson is a board member of the Hall of Fame. Paulson’s areas of expertise include: The First Amendment Paulson founded the Free Speech Center at MTSU in 2019. He was executive director of the First Amendment Center at Vanderbilt University and served as the center’s president and CEO before that. Paulson speaks widely on First Amendment issues and has been quoted extensively in media outlets including the New York Times, Wall Street Journal, USA TODAY, ESPN, CBS Evening 麻豆传媒 and 麻豆传媒week. Paulson has testified before Congress as a First Amendment expert. He has a juris doctorate and is a member of both the Illinois and Florida bars. Paulson was the host of the Emmy-honored television PBS program "Speaking Freely.," As the author of "Freedom Sings," he created a multimedia show celebrating the First Amendment that has toured campuses for the past 20 years. His “The Bill of Rights: The Remix” has been in residency at the Country Music Hall of Fame since 2017. Paulson teaches Mass Media Law and Free Expression, the Media and the American People at MTSU. Journalism Throughout his career, Paulson has drawn on his background as a journalist and lawyer, serving as editor or managing editor of newspapers in five states. He was on the team of journalists who founded USA Today before moving on to manage newsrooms in N.Y., Wis., N.J., Fla., and finally USA TODAY. He and his colleague John Seigenthaler spoke to more than 5,000 journalists and media professionals about the importance of a free press. Popular Music Paulson has written professionally about music over four decades, beginning at the Chicago-based Environs Magazine. He currently hosts the NPT show “The Songwriters” as well as the “Americana One” radio show and podcast. He created “Music Matters,” a radio feature that celebrates songs with impact. Paulson is a member of MTSU’s Recording Industry faculty and teaches History of the Recording Industry. Paulson is a member of the Tennessee Entertainment Commission and a former member of The Mayor’s Music Council in Nashville. Honors He was named fellow of the Society of Professional Journalists, "the highest honor SPJ bestows upon a journalist for extraordinary contributions to the profession." He has received the Robert S. Abbott Memorial Award for Meritorious Service in Mass Communications from the Southern Regional Press Institute. He was elected to the University of Illinois’ Illini Publishing Hall of Fame. Paulson was honored with the American Press Institute Lifetime Service Award. He has received the Missouri Honor Medal for Distinguished Service in Journalism. He is a graduate of the University of Illinois College of Law and the University of Missouri School of Journalism.

Weiner directs a translational molecular immunology research team focused on creating novel immunotherapy approaches for disease prevention and treatment using synthetic nucleic acid technology. Accomplishments of the team and collaborators include the first clinical studies of DNA vaccines, with a focus on advances in gene optimization and electroporation (EP)-mediated DNA delivery. Their work has revitalized the field, rapidly and safely moving new advances into human studies. These include the world鈥檚 first Zika vaccine, the first MERS vaccine, an advanced Ebola Vaccine, and a novel HIV vaccine, among others. Additionally, the Weiner laboratory has helped to develop immunotherapy approaches that are currently in clinical testing for HPV-associated cancer, prostate and other cancers. The first clinically efficacious therapeutic DNA vaccine for HPV cervical intraepithelial neoplasia CIN) has moved into a licensure trial (REVEAL). Weiner and his lab have received several awards/honors for their accomplishments, including the Vaccine Industry Associations Outstanding Academic Research Laboratory (2015 & 2016), being named one of the Top 20 Translational Research Laboratories of the Year (Nature Biotechnology 2016, 2017 &  2018) and the 2014 Stone family Award for Cancer Research. Weiner was named one of the nation鈥檚 top 40 most influential vaccine scientists in 2014, received the 2011 NIH Directors Translational Research Award and is an elected fellow of the American Association for the Advancement of Science since 2011 and a fellow of the International Society for Vaccines, for which he served as president from 2018 to 2020. Weiner is an avid trainer, advisor and advocate for students, fellows and junior faculty as he is highly committed to developing the careers of young scientists.  

Weiner received his B.S. in biology from Stony Brook University, N.Y., and his M.S. in biology from the University of Cincinnati. He then earned a Ph.D. in developmental biology with a focus on molecular immunology from the University of Cincinnati, College of Medicine. Weiner joined the University of Pennsylvania as a research fellow in the Department of Pathology and Laboratory Medicine, where he rose through the ranks to become Professor. He held a second appointment from The Wistar Institute from 1990 to 1993. At Penn, he served as co-chair of the Tumor Virology Program of the Abramson Cancer Institute and as chair of the Gene Therapy and Vaccine Training Program.

Physician-scientist Dr. David Maloney is at the forefront of clinical trials to develop cell therapies for blood and other cancers, including understanding side effects of CAR T鈥檚 and how to deliver them in outpatient settings. A renowned researcher and clinician focusing on cancer immunotherapies and CAR T-cell therapies, he recently presented findings from the TRANSCEND trial for CD19 CAR T. This study showed that patients had improved quality-of-life (reduced fatigue and pain symptoms) starting six months after receiving CAR T-cell therapy. 

Dr. Maloney focuses on using genetically engineered T cells (such as CAR-T) to treat patients with leukemia, lymphoma, myeloma and selected other cancers without causing graft vs. host disease that has been associated with transplantation.  He was instrumental in developing and testing rituximab, the first antibody-based cancer drug on the market 鈥� one that has transformed the treatment of certain leukemias and lymphomas.

He is also an expert on blood-forming (hematopoietic) stem cell transplantation (HCT) in using a matched donor鈥檚 (allogeneic) or a patient鈥檚 own (autologous) stem cells in treatments for patients with hematologic malignancies. Recognizing that standard pre-transplant regimens are too toxic for many patients, Dr. Maloney and Fred Hutch colleagues are evaluating approaches that use antibodies to deliver radioactivity or cancer-killing drugs directly to tumors. They have also developed a less toxic, 鈥渞educed intensity鈥� (nonmyeloablative) regimen that can more safely provide long-term remissions for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin Lymphoma (NHL) and myeloma after allogeneic HCT.

Autologous HCT followed by reduced intensity allogenic HCT (tandem HCT) has proven effective for refractory NHL and myeloma patients. Dr. Maloney and colleagues have learned that nearly all of the anti-tumor activity of allogeneic HCT comes from the specific graft-vs-tumor activities of donor immune T cells, showing that antitumor immunity can be curative. Unfortunately, these T cells can also cause dangerous 鈥済raft-vs-host鈥� effects on normal tissues.

Dr. Maloney continues exploring the use of antibodies as anti-cancer therapies, including newer anti-CD20 antibodies (e.g. ofatumumab, Arzerra庐) for NHL patients, as well as radiolabeled antibodies, drug-carrying antibodies and unlabeled antibodies as targeted pre-transplant 鈥渃onditioning鈥� or as 鈥渕aintenance鈥� to extend remissions after allogeneic transplantation.

As medical director of the Cellular Immunotherapy Integrated Research Center at Fred Hutch, Dr. Maloney cares for patients at the Bezos Family Immunotherapy Clinic at Seattle Cancer Care Alliance, the Hutch鈥檚 clinical-care partner. He is also professor of medicine in the Division of Oncology at the University of Washington.

While many researchers worldwide are trying to find cures for cancer, Dr. Gary Lyman has an equally daunting task: finding a cure for cancer鈥檚 skyrocketing costs and the financial toll it can take on patients and their families.

Dr. Lyman is an internationally recognized thought leader in cancer care delivery, supportive care and health care policy. His research compares the effectiveness of novel diagnostic and therapeutic strategies; examines clinical decision-making; explores risk modeling and precision medicine; assesses health technology research and synthesis; and delves into the factors that drive disparities in cancer care. 

In 2018, he co-co-authored a New England Journal of Medicine paper on biosimilars and what their imminent debut might mean for cancer patients, the health care industry and society. He also led an American Society of Clinical Oncology (ASCO) panel that published a position statement on biosimilars in the Journal of Clinical Oncology.

A medical oncologist, hematologist and public health researcher who focuses on comparative effectiveness, health technology assessment, and health services and outcomes research, he also is interested in cancer prevention, pharmaco-economics, and cancer treatment and supportive care for the elderly. 

Dr Lyman is among the top 1% of investigators by citations in Web of Science. In addition to his work at the Hutch, Dr. Lyman holds leadership positions within the American Society of Clinical Oncology as well as the SWOG Cancer Research Network, for which he serves as executive officer for Cancer Care Delivery, Symptom Control and Quality of Life Research.

Dr. Lyman serves as a senior lead for health care quality and policy within the Hutchinson Institute for Cancer Outcomes Research, or HICOR.

Bonni Lee Guerin, M.D. is a hematologist/oncologist and director of the Breast Cancer Treatment and Prevention Program at Overlook Medical Center, Summit, NJ where she also serves as chair of the Breast Panel, the Multidisciplinary Breast Tumor Board and director of Oncology Education.  

She is the principal investigator of numerous clinical trials exploring new ways to incorporate the latest advances in the management of breast cancer. She is also actively involved in the delivery of highly-specialized immunotherapy, IL-2, for the treatment of melanoma and kidney cancer.

As a medical oncologist with more than 20 years of experience, Dr. Guerin is dedicated to providing the most up to date, cutting edge treatment while looking at each of her patients as an individual. Her philosophy is one of collaboration, working with all members of the care team to provide the best outcome possible. Dr. Guerin believes that compassion and being a good listener, traits she learned from her mother, help tailor a treatment plan that reflects not only the highest order of medical care, but also one that uniquely reflects each and every patient. Dr. Guerin believes it is just as much about living well as it is living long.

Dr. Guerin earned her M.D. at SUNY Stony Brook in 1988, continued her residency at Vanderbilt University in Nashville and completed her fellowship in oncology/hematology at University of California San Diego Cancer Center.  She is board certified in clinical oncology and internal medicine.

Since 2002, Dr. Guerin has served as chair of the Women鈥檚 Oncology Forum, Network for Oncology Communication and Research (NOCR) 鈥� a national organization.  She is a diplomate of the American Society of Clinical Oncology (ASCO) and is a recipient of the Pfizer Award for Excellence in Biochemical Research and a Member of the Expert Panel Consensus Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma.  

She has been named by Castle Connelly as one of NY/Metro Top Doctors for the last 10 years, as well as a Top Doctor for Women's Health. She has recently been honored by Curemonos, a New Jersey non-profit organization dedicated to supporting medically underserved women with breast cancer, was the keynote speaker at the American Cancer Society Relay for Life in Chatham, NJ; and was honored at the Society鈥檚 2019 Diamond Ball, in Woodland Park, NJ. 

Her interests are in breast cancer, hepatobiliary cancer and immunotherapy.  

Dolan, co-editor of the American Journal of Political Science, is the author of “When Does Gender Matter? Women Candidates and Gender Stereotypes in American Elections.” She can talk about gender and elections, women candidates for office, the gender gap in voting, and how gender stereotypes might affect women candidates. Dolan also can speak about political participation, public opinion and electoral and legislative politics.

In the quest for molecular-level information, molecular-scale tools are a powerful and desirable scientific goal. Our research program is centered on development of a new class of nanofabricated devices based on nanopores.

In its simplest form, a nanopore is nothing more than a molecular-sized hole in an insulating membrane. Yet even in this configuration, it is cable of being used to detect and manipulate single molecules. With careful device engineering, it is possible to create powerful sensors for the detection of disease biomarkers at low levels early in the onset of disease or of trace amounts of toxins -- to name two targets. Configured differently, nanopore-based devices can be used to probe intermolecular interactions that underpin biological function -- ranging from testing new pharmaceutical drug candidates to exploring the fundamental biophysics governing processes such as antibody-antigen recognition.

Our research is focused on conceiving, fabricating and optimizing the nanopore devices that will make possible these challenging goals.

Research Interests include:

How do molecules work, and how can we better put them to work for us? Bioanalytical, biophysical, & materials chemistry and nanoscience.

Dr. Priyanka Sharma is an oncologist in Fairway, Kansas and is affiliated with University of Kansas Hospital. She received her medical degree from Baroda Medical College and has been in practice between 11-20 years.

Her specialties are: oncologists diagnose and treat cancers of all types. They use diagnostic tools like biopsies, endoscopies, X-ray and other imaging, nuclear medicine, and blood tests. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors.

Roy A. Jensen, M.D. earned his bachelor鈥檚 degree in Biology and Chemistry from Pittsburg State University in 1980. He graduated from Vanderbilt University School of Medicine in 1984, and remained there to complete a residency in Anatomic Pathology and a Surgical Pathology fellowship under the direction of Dr. David L. Page. Following his clinical training he accepted a biotechnology training fellowship at the National Cancer Institute in the laboratory of Dr. Stuart Aaronson. He returned to Vanderbilt in 1991 and was appointed an assistant professor in the Departments of Pathology and Cell Biology. In 1993 Dr. Jensen was appointed as an investigator in the Vanderbilt-Ingram Cancer Center and assumed the management of the Human Tissue Acquisition and Pathology Shared Resource.  Dr. Jensen was promoted to associate professor of Pathology and Cell Biology in 1996, and was appointed as an associate professor of Cancer Biology in 2001.

In 2004, Dr. Jensen returned home to Kansas and was appointed the William R. Jewell, M.D. Distinguished Kansas Masonic Professor, the director of The University of Kansas Cancer Center, the director of the Kansas Masonic Cancer Research Institute, professor of Pathology and Laboratory Medicine, and professor of Anatomy and Cell Biology at the University of Kansas Medical Center. He also holds appointments as a professor in the Department of Molecular Biosciences at the University of Kansas-Lawrence and as professor in Cancer Biology at The University of Kansas Medical Center. Dr. Jensen is currently serving as president of the Association of American Cancer Institutes (AACI) and is a member of several scientific and professional societies including the American Association for Cancer Research, the American Association for the Advancement of Science, the American Society for Cell Biology, the American Society for Investigative Pathology, and the United States and Canadian Academy of Pathology. He currently has over 150 scientific publications and has lectured widely on the clinical and molecular aspects of breast cancer pathology. Dr. Jensen's research interests are focused on understanding the function of BRCA1 and BRCA2 and their role in breast and ovarian neoplasia; and in the characterization of premalignant breast disease both at the morphologic and molecular levels. His laboratory was instrumental in demonstrating the role of BRCA1 in the growth control of normal and malignant cells and in how loss of functional BRCA1 contributes to the development of breast cancer.

Since becoming director of The University of Kansas Cancer Center in 2004, he has recruited a world-class leadership team and successfully led that team in achieving designation for The University of Kansas Cancer Center as a National Cancer Institute designated cancer center.

Weijing Sun, MD, FACP, is a Director of Division of Medical Oncology in University of Kansas School of Medicine, and an Associate Director of University of Kansas Cancer Center. He specializes in the treatment of colorectal cancer.

Dr. Sun is board-certified in internal medicine and medical oncology. He received his medical degree from Shanghai Medical College, Fudan University, in Shanghai. He completed his residency in internal medicine at Loyola University Medical Center in Maywood, Ill., and his hematology-oncology fellowship at the University of Pennsylvania in Philadelphia.

Dr. Sun is a member of the American Medical Association, the American Society of Clinical Oncology, the American Association of Cancer Research, the Eastern Cooperative Group of Oncology Gastrointestinal Cancer Core Committee, the American College of Physicians 鈥� Internal Medicine, the NCI Gastrointestinal Cancer Steering Committee Hepatobiliary Task Force, and serves on the American Society of Clinical Oncology Scientific Program and Membership Committee. In addition, Dr. Sun has been recognized on U.S. 麻豆传媒 & World Report鈥檚 American Top Doctors list.

Dr. Raphael Gottardo is a computational biologist who specializes in applying rapidly evolving ideas in data science to solving problems in cancer and related diseases. As scientific director of the Translational Data Science Integrated Research Center, he is at the center of the busy intersection of biology, data science and technology at Fred Hutchinson Cancer Research Center.

His goal is to expand data-driven innovations for patients by cultivating a cross-disciplinary environment in which doctors and laboratory scientists work seamlessly with their colleagues in biostatistics and computational sciences to take advantage of the flood of information made possible by advanced technologies. 

The aim is to bring scientific discoveries from research labs to the bedside sooner using data-driven approaches. To do so, bench scientists and clinical researchers from many corners of the Hutch work collaboratively with experts in data science.

Much of his work is focused on profiling the cellular components of the human immune system 鈥� using data science to understand how to make immunotherapies work better for patients. 

鈥淚t鈥檚 when you get into the details that it really becomes interesting,鈥� he said. 鈥淭he immune system is very complex, and it turns out we don鈥檛 know a whole lot about it yet. Looking at these single-cell technologies generating massive amounts of data has brought me to really cool statistical and computational challenges.鈥�

Dr. Gottardo鈥檚 own research involves the development of computational tools for vaccine and immunology studies, including high-throughput experiments that may use flow cytometry or high-speed genome sequencing. His current studies include:
鈥�	Statistical and computational analysis of flow cytometry data
鈥�	Development of statistical and computational methods for single-cell genomics
鈥�	Immune responses to malaria and HIV infection and immunization within the Human Immunology Project Consortium (HIPC)
鈥�	Development of the HIPC database and research portal (www.immunespace.org)
鈥�	Contribution to the Bioconductor project, an open computing resource for genomics
鈥�	Leadership for the Vaccine and Immunology Statistical Center of the Collaboration for AIDS Vaccine Discovery of the Bill and Melinda Gates Foundation
鈥�	Leadership for the Vaccine Statistical Support (VSS) Global Health Vaccine Accelerating Platform (GH-VAP) of the Bill and Melinda Gates Foundation

Dr. Gottardo is the J. Orin Edson Foundation Endowed Chair at Fred Hutch and a member of the Vaccine and Infectious Disease and Public Health Sciences Divisions. He, along with other Fred Hutch researchers, is co-leading a collaboration with the Allen Institute for Immunology to chart the human immune system by harnessing big data and emerging technologies.

An affiliate professor of statistics at the University of Washington, he teaches courses in stochastic modeling, bioinformatics and statistical computing and supervises biostatistics and statistics doctoral students on statistical-methods research for high-dimensional omics data analysis

Dr. David Baskin is board certified by the American Board of Neurological Surgery. He completed his medical training at Mount Sinai School of Medicine of the CUNY, and a residency at the University of California. He completed a fellowship in neural protection at the University of Capetown Medical School. He also completed a fellowship in brain endorphins at the University of California. Baskin is the primary investigator for a number of clinical trials looking at different novel diagnostics and treatments for primary brain tumors and autistic spectrum disorder. His clinical focus is on the treatment of brain and spinal tumors.

Dr. Aldona Spiegel certified in plastic surgery by the American Board of Plastic Surgery. She completed her medical training at the University of Ottawa Faculty of Medicine. Spiegel completed a residency in general surgery and plastic surgery at John Hopkins Hospital. She also completed a residency in plastic surgery and a fellowship in microsurgery at Baylor College of Medicine. Spiegel's clinical focus is microsurgery, breast reconstruction, breast sensation and specialized perforator flaps (DIEP, SIEA, SGAP flaps). Her clinical expertise allows her to focus on research in innovative surgical techniques, such as muscle-preserving flaps.